Passage Bio to Report Fourth Quarter and Full-Year 2020 Financial Results on March 3, 2021
Passage Bio (NASDAQ: PASG) announced a conference call on March 3, 2021, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2020 financial results. This call will provide key insights into the company's recent business highlights. Investors can join via phone or through a live audio webcast. The call will be archived for 30 days. Based in Philadelphia, Passage Bio is focused on developing gene therapies for rare central nervous system disorders, collaborating with the University of Pennsylvania to further its preclinical work and enhance its pipeline.
- Partnership with University of Pennsylvania enhances access to gene therapy innovations.
- Focus on developing transformative therapies for rare CNS diseases positions the company in a niche market.
- Scheduled financial call shows accountability and transparency to investors.
- None.
PHILADELPHIA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 3, 2021 to report its fourth quarter and full-year 2020 financial results and discuss recent business highlights.
To access the live conference call, please dial 833-528-0605 (domestic) or 830-221-9711 (international) and refer to conference ID 6758094. A live audio webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. The archived webcast will be available on Passage Bio's website approximately two hours after the completion of the event and for 30 days following the call.
About Passage Bio
At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.
For further information, please contact:
Investors:
Stuart Henderson
Passage Bio
shenderson@passagebio.com
Media:
Gwen Fisher
Passage Bio
215.407.1548
gfisher@passagebio.com
FAQ
When will Passage Bio report its fourth quarter and full-year 2020 financial results?
How can I access the live conference call for Passage Bio's financial results?
What is the focus of Passage Bio's business?
Where is Passage Bio located?
Is there a webcast available for Passage Bio's financial call?
